Although ACE inhibitors and ARBs are foundational therapies in CKD management, clinical data suggest that RAS blockade alone does not fully prevent disease progression, likely due to residual RAS activity and alternative mechanisms contributing to kidney function decline (20). This evidence concerns the gene ACE and chronic kidney disease.